TUDORZA PRESSAIR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TUDORZA PRESSAIR (TUDORZA PRESSAIR).
Long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation.
| Metabolism | Primarily hydrolyzed via esterases in plasma and tissues; not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily non-renal elimination: 54% of the radiolabeled dose recovered in feces, 28% in urine after 7 days. Fecal excretion likely represents unabsorbed drug and biliary elimination. |
| Half-life | Terminal elimination half-life approximately 10 hours, supporting twice-daily dosing in chronic obstructive pulmonary disease. |
| Protein binding | Binding to human plasma proteins is approximately 72%. |
| Volume of Distribution | Volume of distribution at steady state is 165 L (approx. 2.4 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Absolute bioavailability after inhalation is not known; systemic exposure is low due to high local lung deposition and rapid clearance. |
| Onset of Action | Time to bronchodilation onset is within 30 minutes after inhalation; maximum effect seen at 2 hours. |
| Duration of Action | Bronchodilator effect persists for 12 hours, consistent with twice-daily dosing regimen. |
One inhalation (400 mcg aclidinium) orally twice daily.
| Dosage form | POWDER, METERED |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C), use caution. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No dose adjustment required; plasma concentrations similar to younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TUDORZA PRESSAIR (TUDORZA PRESSAIR).
| Breastfeeding | It is not known whether tiotropium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TUDORZA PRESSAIR is administered to a nursing woman. M/P ratio is unknown. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at exposures up to 100 times the maximum recommended human daily inhalation dose. Risk of fetal harm cannot be ruled out. Use during pregnancy only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to tiotropium or any component of the formulation","Hypersensitivity to ipratropium or atropine (due to cross-reactivity)"]
| Precautions | ["Not for acute bronchospasm or initial therapy of acute episodes","Paradoxical bronchospasm may occur","Immediate hypersensitivity reactions reported","Use with caution in narrow-angle glaucoma","Use with caution in urinary retention (e.g., prostatic hyperplasia, bladder neck obstruction)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of bronchospasm, respiratory distress, and anticholinergic effects (e.g., blurred vision, urinary retention). No specific fetal monitoring required beyond routine prenatal care. |
| Fertility Effects | No human data on fertility. Animal studies with tiotropium showed no impairment of fertility at doses up to 0.335 mg/kg/day (approximately 10 times the maximum recommended human daily inhalation dose on a mg/m2 basis). |